Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

  • CEO: Gordon Sanghera
  • Website: www.nanoporetech.com
  • Ticker symbol: Privately held
  • Headquarters: Oxford, UK
  • Number of employees: 250+

ONT called Illumina's revised remedies proposal an "illusory offer" that doesn't offset the anticompetitive effects of an Illumina-PacBio merger.

In a preprint posted on BioRxiv this week, Decode researchers used nanopore sequencing to characterize structural variants in more than 1,800 Icelandic individuals.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.

In a revised remedies proposal to the UK's Competition and Markets Authority, Illumina offered licenses to a wider swath of IP held by it and PacBio.

In a response to the UK CMA's findings that the PacBio deal would lessen competition, Illumina said it would be open to licensing some IP to Oxford Nanopore.

A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service. 

Using 350 human genomes from different populations, the two centers plan to develop a multi-genome reference sequence that is as complete as possible.

The firm said CRISPR will enable targeted sequencing of long regions of interest that were previously only accessible with long-read whole-genome sequencing.

The UK-based sequencing technology firm continues to seek invalidation of PacBio's patents, despite unsuccessful earlier efforts.

The company believes that Xdrop will find adopters in academia and clinical research, although diagnostics is on its radar.

Pages

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.